{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:37Z","timestamp":1763017837127,"version":"3.37.3"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen-Cilag SpA","award":["TMC278HTX4002"],"award-info":[{"award-number":["TMC278HTX4002"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191300","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T13:25:03Z","timestamp":1518787503000},"page":"e0191300","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4230-2424","authenticated-orcid":true,"given":"Nadia","family":"Galizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Carini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Bigoloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Tambussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Termini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"issue":"9787","key":"ref1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"for ECHO Study Group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"J-M Molina","year":"2011","journal-title":"Lancet"},{"issue":"9787","key":"ref2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"for THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment naive adults infected with HIV (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"CJ Cohen","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1310\/hct1403-81","article-title":"Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine\/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies","volume":"14","author":"MR Nelson","year":"2013","journal-title":"HIV Clin Trials"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/23744235.2016.1194528","article-title":"Optimizing the virological success of tenofovir DF\/FTC\/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection","volume":"48","author":"C Bernaud","year":"2016","journal-title":"Infect Dis (Lond)"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/jac\/dku294","article-title":"Initiation of rilpivirine, tenofovir and emtricitabine (RPV\/TDF\/FTC) regimen in 363 patients with virological vigilance assessment in \u2018real life\u2019","volume":"69","author":"C Amiel","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref6","first-page":"172","article-title":"Recent advances in rilpivirine: new data and promising treatment option","volume":"16","author":"JL Casado","year":"2014","journal-title":"AIDS Reviews"},{"key":"ref7","unstructured":"Edurant \u00ae Summary of Product Characteristics."},{"issue":"41","key":"ref8","doi-asserted-by":"crossref","first-page":"e5146","DOI":"10.1097\/MD.0000000000005146","article-title":"The efficacy and safety often of oviralafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis","volume":"95","author":"H Wang","year":"2016","journal-title":"Medicine"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"e0162320","DOI":"10.1371\/journal.pone.0162320","article-title":"Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment","volume":"11","author":"G Lapadula","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"ref10","first-page":"19","article-title":"Is switching to Kivexa with rilpivirine as effective as switching to Eviplera in clinical practice?","volume":"17","author":"N Marshall","year":"2016","journal-title":"HIV Med"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10096-016-2602-3","article-title":"Efficacy and safety of switching to abacavir\/lamivudine (ABC\/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART","volume":"35","author":"R Palacios","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"e0164455","DOI":"10.1371\/journal.pone.0164455","article-title":"Abacavir\/Lamivudine plus Rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study","volume":"11","author":"J Troya","year":"2016","journal-title":"PlosOne"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1093\/jac\/dkw347","article-title":"Effectiveness and safety of an abacavir\/lamivudine plus rilpivirine regimen for the treatment of HIV-1 infection in naive patients","volume":"71","author":"A Curran","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/QAD.0000000000000103","article-title":"Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity","volume":"28","author":"JC Yombi","year":"2014","journal-title":"AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"20037","DOI":"10.7448\/IAS.18.1.20037","article-title":"Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy","volume":"18","author":"N Gianotti","year":"2015","journal-title":"J Int AIDS Soc"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:32:21Z","timestamp":1588962741000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191300"}},"subtitle":[],"editor":[{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191300","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,2,16]]}}}